The rule of fives, a simple way to stratify risk for primary gastrointestinal stromal tumors (GIST) by Robert G Maki
CLINICAL SARCOMA RESEARCH
Maki Clinical Sarcoma Research 2012, 2:21
http://www.clinicalsarcomaresearch.com/content/2/1/21LETTER TO THE EDITOR Open AccessThe rule of fives, a simple way to stratify risk for
primary gastrointestinal stromal tumors (GIST)
Robert G MakiAbstract
The current AJCC version 7 staging system is a lugubrious means to classify gastrointestinal stromal tumors with
respect to their risk and need for adjuvant systemic therapy. The rule of fives, suggested here, is a means to quickly
assess whether a given gastrointestinal stromal tumor is low vs intermediate-high risk.
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Risk stratification for primary gastrointestinal stromal
tumors (GISTs) has evolved with the understanding of
the disease, spurred by its demonstration as a specific
sarcoma subtype. GISTs most commonly contain an ac-
tivating mutation in KIT, or much less commonly in
PDGFRA; even rarer forms of GIST have other genetic
alterations. Risk stratification is critical, since three years
of adjuvant imatinib is now considered a standard of
care for patients with intermediate to high risk primary
GIST.
Risk criteria were first published in 2001 and were
amended as more was learned about the importance of
mitotic rate, anatomic primary site, and size, in large
part due to large case series developed by Miettinen,
Lasota and colleagues [1,2]. These factors have been
incorporated into a nomogram [3], risk heat map and
detailed staging system [4], and have been incorporated
into the most recent (7th) edition of the American Joint
Committee on Cancer (AJCC) staging manual.
The nomenclature for staging involves a number of
details that may be difficult to remember for an uncom-
mon tumor. The collective data suggest a simple way to
deduce low risk vs. intermediate-high risk GISTs. The
“rule of fives” states that intermediate to high risk gastric
GISTs are both more than 5 cm in size and have more
than 5 mitoses (mit) per 50 high powered fields (hpf ).
Conversely, nonCXgastric GISTs are high grade if they
are either more than 5 cm in size or have more thanCorrespondence: bobmakimd@gmail.com
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reproduction in any medium, provided the or5 mit/50 hpf. With this simple “and/or” construct, all
the GISTs with over 50% risk of recurrence are cap-
tured, as are an intermediate risk group of 5–10 cm
small bowel GIST with low mitotic rate (24% recur-
rence risk, Miettinen prognostic group 3a).
This rule is particularly useful to highlight the situ-
ation of a common but surprisingly low risk GIST, i.e.
those gastric GISTs that are >5 cm and have a low mi-
totic rate. Since the recurrence risk of these GISTs is
12% or less per Miettinen and colleagues [1,2], these
patients are potentially good candidates for observation
alone after primary surgery.
Further nuances will arise as exact mutation rate and
KIT or PDGFRA mutation status are incorporated into
staging. However, exon 9 KIT mutations (~15% of GIST)
are nearly exclusively found in a small bowel primary
site, and uncommon PDGFRA mutations are usually
associated with a gastric primary site. As a result, future
patient staging efforts should not prove unduly cumber-
some, and can build on this simple rule.Competing interest
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